ClinicalTrials.gg
RecruitingNCT06317519Updated Mar 19, 2024

Verify the Performance in Clinical Practice of the Immersive Virtual Reality Platform GRAIL (Gait Real-time Analysis Interactive Lab)

An observational study in Acquired Brain Injury and Cerebral Palsy, sponsored by IRCCS Eugenio Medea. Recruiting at 1 site in Italy. Open to participants aged 5 Years to 20 Years. Per ClinicalTrials.gov, last updated 2024-03-19.

Sponsored by IRCCS Eugenio Medea · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Apr 2026, 7 months ago, but the record still lists the study as recruiting.
  • Started Apr 2021; still recruiting 5 years 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
100
Ages
5 Years to 20 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 11 studies in Brain Injuries by IRCCS Eugenio Medea — 4 open to participants now, 4 under way, none of them phase 3. Brain Injuries · IRCCS Eugenio Medea.

Started
2021
the only one that year
Observational
6 of 11
3 open now
Registered
9th of 11
by date

Among the 11 studies in Brain Injuries by IRCCS Eugenio Medea, this one is the only one that started in 2021, is one of 6 observational ones, and was the 9th registered.

Brain Injuries

947 studies on the registry are indexed under Brain Injuries; 234 are open to participants now.

Browse Brain Injuries studies →

Open to participants now

4 of the 11 studies in Brain Injuries by IRCCS Eugenio Medea are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Where they have run

Who these studies take

Of the 152 Brain Injuries studies recruiting now, 77 (51%) set no upper age limit and 53 (35%) stop at 75 or younger; 38 take children under 18; 23 take healthy volunteers.

This study: 5 Years to 20 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies in Brain Injuries by IRCCS Eugenio Medea, or all of them as a file.
02

Study summary

Gait pattern difficulties, balance and coordination deficits often characterize patients with congenital and acquired neuromotor disorders and have a significant impact on the quality of life of these subjects. There are various treatments used and in recent years, the advent of advanced technologies in rehabilitation and, in particular, devices based on virtual reality, has opened up new possibilities in rehabilitation. Virtual reality is a promising strategy that incorporates many principles crucial to motor learning, such as high-intensity, repetitive, goal-oriented tasks, enhanced synchronized sensory signals, and active participation. The virtual environment is also suitable for personalized treatment based on the needs of the individual patient.

The GRAIL (Gait Real-time Analysis Interactive Lab) is a device that integrates immersive virtual reality with an instrumented treadmill and a motion capture system, which can be used with both rehabilitation and evaluation goals. To date, there are still few studies of this device in the pediatric field.

The objective of the study is to verify the performance in clinical practice of the immersive virtual reality platform GRAIL and determine any secondary effects by evaluating whether they entail acceptable risks compared to the expected performances following the protocol defined at the IRCCS Medea by Bosisio Parini, in children and adolescents with congenital and acquired neuromotor pathology.

Patients suffering from acquired and congenital brain injuries undergo a combined rehabilitation treatment consisting of 20 sessions with GRAIL and 20 physiotherapy sessions in four weeks. The same subjects undergo evaluations before and at the end of the treatment

The study is prospective and involves the verification of performance through clinical and instrumental evaluations in the population of subjects treated with the GRAIL device at the IRCCS Medea-Bosisio Parini.

03

Conditions studied

  • Acquired Brain Injury
  • Cerebral Palsy
04

Who can participate

Ages eligible
5 Years to 20 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Children aged 5 to 20 with either cerebral palsy or acquied brain injury, who can follow verbal orders and are not disabled regarding senses or intellect

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Capable of following verbal requests
  • Gross Motor Function Classification System score I to III

Exclusion criteria

Exclusion Criteria:

  • Severe spasticity
  • Severe cognitive disability
  • Severe auditory or visual disability
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
100 participants (estimated)
Patient registry
No

Groups and cohorts

  • Physical Rehabilitation + GRAIL

    Patients in this group receive Physical Rehabilitation and GRAIL treatment

    Procedure: Physical Rehabilitation · Device: Gait Real-time Analysis Interactive Lab

  • Physical Rehabilitation

    Patients in this group receive Physical Rehabilitation not GRAIL treatment

    Procedure: Physical Rehabilitation

Interventions

  • ProcedurePhysical Rehabilitation

    5 sessions of physical rehabilitation per week. Each session lasting 45 minutes. Overall 20 sessions = 4 weeks.

  • DeviceGait Real-time Analysis Interactive Lab

    5 sessions of GRAIL assisted rehabilitation per week. Each session lasting 45 minutes. Overall 20 sessions = 4 weeks.

06

What researchers measure

Primary outcomes

  1. 6 minute walking test

    Distance walked over 6 minutes, in meters

    Time frame: Before and after 4 weeks of treatment

  2. Gross Motor Function Measure -total score

    Total score on the Gross Motor Function Measure. Greater scores indicate better performance

    Time frame: Before and after 4 weeks of treatment

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2021 (actual). Primary completion is estimated for Apr 2026, 60 months after the start.

Of 144 non-industry observational studies under Brain Injuries, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 73. This study's planned 60 months is above that.

Counting every sponsor, half of 149 studies reached it within 31 months; a quarter within 16 and three quarters within 73.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 12, 2024
First posted
Mar 19, 2024
StartActual
Apr 12, 2021
Primary completionEst.
Apr 12, 2026
CompletionEst.
Apr 12, 2026
Last update
Mar 19, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 19, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06317519
Responsible party
Sponsor
First posted
Mar 19, 2024
Start date
Apr 12, 2021
Primary completion
Apr 12, 2026 (estimated)
Completion
Apr 12, 2026 (estimated)
Last update
Mar 19, 2024

Study contacts

Elena Beretta, MD
Contact
elena.beretta@lanostrafamiglia.it
031877851 ext. +39

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion